SBLENDORIO GLENN 4

What Happened Glenn Sblendorio, a director of 4D Molecular Therapeutics (FDMT), received a 50,000-share derivative award on June 17, 2026. The award is reported at an acquisition price of $0.00 (i.e., a compensatory stock-option type grant) and no cash was exchanged. This is an award/compensation grant rather than a market purchase or sale.

Key Details

• Transaction date: June 17, 2026; Form 4 filed June 18, 2026 (timely filing).
• Instrument: Derivative award (stock option grant) for 50,000 shares; acquisition price reported as $0.00; total reported cash value $0.
• Vesting (per filing footnotes): 1/3 vests on June 17, 2027, then in equal monthly installments thereafter until fully vested on June 17, 2029. The options also vest in full upon a Change in Control.
• Grant mechanics: Automatically granted under the company’s non-employee director compensation program.
• Shares owned after transaction: Not specified in the provided excerpt.

Context This was a routine director compensation grant (derivative/option award), not an exercise or sale. The award does not represent immediate sale proceeds or a cash purchase; vesting schedule determines when the director can exercise the options. Such grants are common for non-employee directors and primarily reflect compensation policy rather than an immediate insider market signal.